1 Result: Comerica
Mirati Therapeutics' KRAZATI Faces Setback; Comerica Q2 Earnings Beat
July 21st, 2023
Mirati Therapeutics, Inc. (Nasdaq: MRTX) faced a setback when the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the Conditional Marketing Authorisation Application (MAA) for its dr. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
November 06th, 2026
Operation Economic Outcast Severs MEXC Global's Access to the U.S. Financial System
November 06th, 2026November 06th, 2026
Member Login